Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 865101, 9 pages
http://dx.doi.org/10.1155/2015/865101
Review Article

Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

1Cancer Research UK Centre, University of Southampton, Southampton SO16 6YD, UK
2Department for Health Economics, University of Bielefeld, 33501 Bielefeld, Germany
3PAREXEL International, 160 Euston Road, London NW1 2DX, UK
4Bristol-Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08543, USA

Received 7 July 2014; Accepted 31 October 2014

Academic Editor: Swaleha Zubair

Copyright © 2015 Peter Johnson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Material 1 provides an overview of the objectives, methodology, outcomes and limitations, and results of the literature review conducted to define how various stakeholders describe cure in oncology.

Supplementary Material 2 provides an overview of the objectives and outcomes and limitations of the literature review conducted to identify the clinical endpoints currently used in malignant melanoma, non-small cell lung cancer, and renal cell carcinoma trials.

  1. Supplementary Material